Anjali Acharya
Internal Medicine · Bronx, NYNPI 1003903444
Payments from drug & device makers
Across 94 payments — averaging $2203.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$112K
- Boehringer Ingelheim$33K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$25K
- GSK$19K
- Vifor (international) Ltd.$16K
- Boehringer Ingelheim International GmbH$2K
- plus $808 from 11 others
Across 11 payments — averaging $118.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Consulting fees$13,43568%
- Travel & lodging$5,02426%
- Food & beverage$1,1506%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $112,448 |
| Boehringer Ingelheim | 6 | $32,798 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $25,055 |
| GSK | 15 | $18,821 |
| Vifor (international) Ltd. | 14 | $15,594 |
| Boehringer Ingelheim International GmbH | 2 | $1,591 |
| AstraZeneca | 14 | $273 |
| Vifor Pharma, Inc. | 7 | $132 |
| Amgen | 5 | $119 |
| Aurinia Pharma U.S., Inc. | 3 | $64 |
| Akebia Therapeutics Inc | 2 | $51 |
| Travere Therapeutics, Inc. | 2 | $43 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Bayer | 1 | $31 |
| Novartis | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
How this compares
$207,115 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.